SCHEMBL16375208

SCHEMBL16375208

CC(CC(=O)O)NC(=O)C(Cc1ccc(-c2ncc(-c3ccccc3)cn2)cc1)NC(=O)c1cccs1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSPA5 P11021 5/20 0.51
▸ HSPA2 P54652 3/20 0.51
▸ HSPA9 P38646 2/20 0.51
▸ CTSL P07711 1/20 0.51
▸ HSPA1A P0DMV8 1/20 0.51
▸ HPGD P15428 1/20 0.45
▸ HPGDS O60760 3/20 0.43
▸ MMEL1 Q495T6 1/20 0.41
▸ USP30 Q70CQ3 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ CTSB P07858 1/20 0.41
▸ CTSS P25774 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ KLKB1 P03952 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17994242 0.93 HSPA5 (0.48) HSPA5HSPA2HSPA9CTSLHSPA1A
SCHEMBL16375203 0.89 CTSL (0.53) HSPA5HSPA2HSPA9CTSLHSPA1A
SCHEMBL16375204 0.88 CTSS (0.50) CTSLMMEL1CTSBCTSSCTSK
SCHEMBL16375213 0.85 HSPA1A (0.53) HSPA5HSPA2HSPA9CTSLHSPA1A
SCHEMBL16375233 0.84 CTSL (0.54) HSPA5HSPA2HSPA9CTSLHSPA1A
SCHEMBL17994244 0.82 PSMB5 (0.47) CTSLMMEL1CTSBCTSSCTSK
SCHEMBL16375201 0.81 CTSL (0.53) HSPA5HSPA2HSPA9CTSLHSPA1A
SCHEMBL17994243 0.81 HSPA5 (0.50) HSPA5HSPA2HSPA9CTSLHSPA1A
SCHEMBL17994251 0.78 HSPA5 (0.50) HSPA5HSPA2HSPA9CTSLHSPA1A
SCHEMBL17994240 0.78 CTSL (0.53) HSPA5HSPA2HSPA9CTSLHSPA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9598430-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-03-21 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R HSPA5 3669/4885HSPA2 3462/4885HSPA9 2536/4885
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R HSPA5 3669/4885HSPA2 3462/4885HSPA9 2536/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R HSPA5 3669/4885HSPA2 3462/4885HSPA9 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback